Chromosome Analysis, Leukemic Blood

Leukemia is not located on a single chromosome; it often involves chromosomal abnormalities. The best-known is the Philadelphia chromosome, a translocation between chromosomes 9 and 22 (t(9;22)) that creates the BCR‑ABL fusion gene on derivative chromosome 22, commonly seen in chronic myeloid leukemia and some acute lymphoblastic leukemias. Other leukemias involve different translocations (e.g., t(15;17), t(8;21)); these findings guide diagnosis and treatment.

In a blood test, leukemia is suggested by an abnormal white blood cell count (very high or sometimes low), presence of immature “blast” cells on the peripheral smear, anemia (low hemoglobin), and thrombocytopenia (low platelets). The differential shows abnormal proportions of white cell types and atypical cell morphology. Elevated LDH and unexplained cytopenias often prompt bone marrow biopsy for definitive diagnosis.

Leukemia often features recurrent chromosomal abnormalities, including the Philadelphia chromosome t(9;22) (BCR‑ABL), t(15;17) PML‑RARA (acute promyelocytic leukemia), t(8;21) and inv(16)/t(16;16) (AML subtypes), t(12;21) ETV6‑RUNX1 (pediatric ALL), MLL (11q23) rearrangements, trisomy 8 or monosomy 7, hyper- or hypodiploidy, and complex karyotypes. Also common are deletions such as del(5q), del(7q) and isochromosome 17q.

Karyotype in leukemia refers to the chromosomal complement of malignant cells and commonly shows specific abnormalities rather than a single pattern. Frequent findings include t(9;22)(q34;q11) (BCR‑ABL), t(15;17) (PML‑RARA), t(12;21) (ETV6‑RUNX1), as well as trisomies, monosomies and complex karyotypes. These cytogenetic changes are used for diagnosis, risk stratification and treatment planning. They vary by subtype and age.

Leukemia arises from genetic changes in blood-forming cells—most are acquired (somatic) mutations and chromosomal abnormalities like translocations, deletions, or amplifications that disrupt genes controlling growth. A small proportion reflects inherited predisposition from familial gene mutations or syndromes. Environmental exposures (radiation, chemotherapy, benzene) can increase risk by causing DNA damage. Diagnosis relies on detecting these genetic/chromosomal alterations.

p190 BCR‑ABL1 is a fusion protein from the Philadelphia chromosome translocation (t(9;22)) that produces a constitutively active BCR‑ABL tyrosine kinase of about 190 kDa. It’s most commonly found in Philadelphia‑positive acute lymphoblastic leukemia, driving unchecked cell proliferation and survival. Molecular detection informs prognosis and enables targeted treatment with tyrosine kinase inhibitors like imatinib or dasatinib.